Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.

Ramaswamy Govindan, Howard McLeod, Prasad Mantravadi, Naomi Fineberg, Paul Helft, Kenneth Kesler, Nasser Hanna, Cindy Stoner, Rafat Ansari, Edward Fox

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Esophageal cancer frequently expresses cyclooxygenase-2 (COX-2) enzyme. In preclinical studies, COX-2 inhibition results in decreased cell proliferation and potentiation of chemotherapy and radiation. We report preliminary results of a phase II study conducted by the Hoosier Oncology Group in patients with potentially resectable esophageal cancer. All patients received cisplatin at 75 mg/m2 given on days 1 and 29 and fluorouracil (5-FU) at 1000 mg/m2 on days 1 to 4 and 29 to 32 with radiation (50.4 Gy beginning on day 1). Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years. Esophagectomy was performed 4 to 6 weeks after completion of chemoradiation. The primary study endpoint was pathologic complete response (pCR). Secondary endpoints included response rate, toxicity, overall survival, and correlation between COX-2 expression and pCR. Thirty-one patients were enrolled from March 2001 to July 2002. Respective grade 3/4 toxicities were experienced by 58%/19% of patients, and consisted of granulocytopenia (16%), nausea/vomiting (16%), esophagitis (10%), dehydration (10%), stomatitis (6%), and diarrhea (31%). Seven patients (24%) required initiation of enteral feedings. There have been seven deaths so far, resulting from postoperative complications (2), pulmonary embolism (1), pneumonia (1), and progressive disease (3). Of the 22 patients (71%) who underwent surgery, 5 had pCR (22%). We conclude that the addition of celecoxib to chemoradiation is well tolerated. The pCR rate of 22% in this study is similar to that reported with the use of preoperative chemoradiation in other trials. Further follow-up is necessary to assess the impact of maintenance therapy with celecoxib on overall survival.

Original languageEnglish (US)
Pages (from-to)18-21
Number of pages4
JournalOncology (Williston Park, N.Y.)
Volume18
Issue number14 Suppl 14
StatePublished - Dec 2004

Fingerprint

Celecoxib
Esophageal Neoplasms
Fluorouracil
Cisplatin
Cyclooxygenase 2
Radiation Dosage
Stomatitis
Agranulocytosis
Esophagectomy
Survival
Esophagitis
Enteral Nutrition
Pulmonary Embolism
Dehydration
Nausea
Vomiting
Disease Progression
Diarrhea
Pneumonia
Cell Proliferation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Govindan, R., McLeod, H., Mantravadi, P., Fineberg, N., Helft, P., Kesler, K., ... Fox, E. (2004). Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park, N.Y.), 18(14 Suppl 14), 18-21.

Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer : preliminary results. / Govindan, Ramaswamy; McLeod, Howard; Mantravadi, Prasad; Fineberg, Naomi; Helft, Paul; Kesler, Kenneth; Hanna, Nasser; Stoner, Cindy; Ansari, Rafat; Fox, Edward.

In: Oncology (Williston Park, N.Y.), Vol. 18, No. 14 Suppl 14, 12.2004, p. 18-21.

Research output: Contribution to journalArticle

Govindan, R, McLeod, H, Mantravadi, P, Fineberg, N, Helft, P, Kesler, K, Hanna, N, Stoner, C, Ansari, R & Fox, E 2004, 'Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.', Oncology (Williston Park, N.Y.), vol. 18, no. 14 Suppl 14, pp. 18-21.
Govindan, Ramaswamy ; McLeod, Howard ; Mantravadi, Prasad ; Fineberg, Naomi ; Helft, Paul ; Kesler, Kenneth ; Hanna, Nasser ; Stoner, Cindy ; Ansari, Rafat ; Fox, Edward. / Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer : preliminary results. In: Oncology (Williston Park, N.Y.). 2004 ; Vol. 18, No. 14 Suppl 14. pp. 18-21.
@article{3995175efb9949d6bddc050755b3f0c0,
title = "Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results.",
abstract = "Esophageal cancer frequently expresses cyclooxygenase-2 (COX-2) enzyme. In preclinical studies, COX-2 inhibition results in decreased cell proliferation and potentiation of chemotherapy and radiation. We report preliminary results of a phase II study conducted by the Hoosier Oncology Group in patients with potentially resectable esophageal cancer. All patients received cisplatin at 75 mg/m2 given on days 1 and 29 and fluorouracil (5-FU) at 1000 mg/m2 on days 1 to 4 and 29 to 32 with radiation (50.4 Gy beginning on day 1). Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years. Esophagectomy was performed 4 to 6 weeks after completion of chemoradiation. The primary study endpoint was pathologic complete response (pCR). Secondary endpoints included response rate, toxicity, overall survival, and correlation between COX-2 expression and pCR. Thirty-one patients were enrolled from March 2001 to July 2002. Respective grade 3/4 toxicities were experienced by 58{\%}/19{\%} of patients, and consisted of granulocytopenia (16{\%}), nausea/vomiting (16{\%}), esophagitis (10{\%}), dehydration (10{\%}), stomatitis (6{\%}), and diarrhea (31{\%}). Seven patients (24{\%}) required initiation of enteral feedings. There have been seven deaths so far, resulting from postoperative complications (2), pulmonary embolism (1), pneumonia (1), and progressive disease (3). Of the 22 patients (71{\%}) who underwent surgery, 5 had pCR (22{\%}). We conclude that the addition of celecoxib to chemoradiation is well tolerated. The pCR rate of 22{\%} in this study is similar to that reported with the use of preoperative chemoradiation in other trials. Further follow-up is necessary to assess the impact of maintenance therapy with celecoxib on overall survival.",
author = "Ramaswamy Govindan and Howard McLeod and Prasad Mantravadi and Naomi Fineberg and Paul Helft and Kenneth Kesler and Nasser Hanna and Cindy Stoner and Rafat Ansari and Edward Fox",
year = "2004",
month = "12",
language = "English (US)",
volume = "18",
pages = "18--21",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "14 Suppl 14",

}

TY - JOUR

T1 - Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer

T2 - preliminary results.

AU - Govindan, Ramaswamy

AU - McLeod, Howard

AU - Mantravadi, Prasad

AU - Fineberg, Naomi

AU - Helft, Paul

AU - Kesler, Kenneth

AU - Hanna, Nasser

AU - Stoner, Cindy

AU - Ansari, Rafat

AU - Fox, Edward

PY - 2004/12

Y1 - 2004/12

N2 - Esophageal cancer frequently expresses cyclooxygenase-2 (COX-2) enzyme. In preclinical studies, COX-2 inhibition results in decreased cell proliferation and potentiation of chemotherapy and radiation. We report preliminary results of a phase II study conducted by the Hoosier Oncology Group in patients with potentially resectable esophageal cancer. All patients received cisplatin at 75 mg/m2 given on days 1 and 29 and fluorouracil (5-FU) at 1000 mg/m2 on days 1 to 4 and 29 to 32 with radiation (50.4 Gy beginning on day 1). Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years. Esophagectomy was performed 4 to 6 weeks after completion of chemoradiation. The primary study endpoint was pathologic complete response (pCR). Secondary endpoints included response rate, toxicity, overall survival, and correlation between COX-2 expression and pCR. Thirty-one patients were enrolled from March 2001 to July 2002. Respective grade 3/4 toxicities were experienced by 58%/19% of patients, and consisted of granulocytopenia (16%), nausea/vomiting (16%), esophagitis (10%), dehydration (10%), stomatitis (6%), and diarrhea (31%). Seven patients (24%) required initiation of enteral feedings. There have been seven deaths so far, resulting from postoperative complications (2), pulmonary embolism (1), pneumonia (1), and progressive disease (3). Of the 22 patients (71%) who underwent surgery, 5 had pCR (22%). We conclude that the addition of celecoxib to chemoradiation is well tolerated. The pCR rate of 22% in this study is similar to that reported with the use of preoperative chemoradiation in other trials. Further follow-up is necessary to assess the impact of maintenance therapy with celecoxib on overall survival.

AB - Esophageal cancer frequently expresses cyclooxygenase-2 (COX-2) enzyme. In preclinical studies, COX-2 inhibition results in decreased cell proliferation and potentiation of chemotherapy and radiation. We report preliminary results of a phase II study conducted by the Hoosier Oncology Group in patients with potentially resectable esophageal cancer. All patients received cisplatin at 75 mg/m2 given on days 1 and 29 and fluorouracil (5-FU) at 1000 mg/m2 on days 1 to 4 and 29 to 32 with radiation (50.4 Gy beginning on day 1). Celecoxib (Celebrex) was administered at 200 mg orally twice daily beginning on day 1 until surgery and then at 400 mg orally twice daily until disease progression or unexpected toxicities, or for a maximum of 5 years. Esophagectomy was performed 4 to 6 weeks after completion of chemoradiation. The primary study endpoint was pathologic complete response (pCR). Secondary endpoints included response rate, toxicity, overall survival, and correlation between COX-2 expression and pCR. Thirty-one patients were enrolled from March 2001 to July 2002. Respective grade 3/4 toxicities were experienced by 58%/19% of patients, and consisted of granulocytopenia (16%), nausea/vomiting (16%), esophagitis (10%), dehydration (10%), stomatitis (6%), and diarrhea (31%). Seven patients (24%) required initiation of enteral feedings. There have been seven deaths so far, resulting from postoperative complications (2), pulmonary embolism (1), pneumonia (1), and progressive disease (3). Of the 22 patients (71%) who underwent surgery, 5 had pCR (22%). We conclude that the addition of celecoxib to chemoradiation is well tolerated. The pCR rate of 22% in this study is similar to that reported with the use of preoperative chemoradiation in other trials. Further follow-up is necessary to assess the impact of maintenance therapy with celecoxib on overall survival.

UR - http://www.scopus.com/inward/record.url?scp=17944362255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17944362255&partnerID=8YFLogxK

M3 - Article

C2 - 15685829

AN - SCOPUS:17944362255

VL - 18

SP - 18

EP - 21

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 14 Suppl 14

ER -